MHRA Drug Safety Notice 2012. Safety Information on the Use of Blue Dye Patent Blue V. UK National Pharmacovigilence Expert Advisory Group of the Commission on Human Medicines.

has been cited by the following article:

• TITLE: Haemofiltration and Noradrenaline Corrects life-Threatening Cardiovascular Instability Following Delayed Anaphylactic Reaction to Patent Blue Dye in Sentinel Node Biopsy for Breast Cancer

  AUTHORS: Peter K. Donnelly, Louise Robinson, Matt Halkes, Andy Goodman

  KEYWORDS: Blue Dye, Anaphylaxis, Sentinel Node, Haemofiltration, Breast Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.5 No.12, October 23, 2014

  ABSTRACT: The aim of this case report is to present a novel approach to the management of very severe anaphylactic reaction to Patent Blue Dye used in Sentinel Node Biopsy for breast cancer treatment. The severity and duration of cardiovascular effects has not been described previously in this setting. Comprehensive ICU support including heamofiltration resulted in the patients’ complete recovery and successful long-term well-being despite a change to our routine cancer care plan.